With only a patchwork of state cannabis laws currently in existence, these new recommendations offer a unified federal framework to help optimize the care of patients across the country.
Californian cannabis users could be put at serious risk from fungal and bacterial contaminants as new regulations lack effective safety screenings, despite the state’s Quality Control Committee specifically advocating for such tests.
The American Osteopathic Association supports the reclassification of cannabis as a Schedule II Drug to facilitate advancement in clinical, public health, patient safety and health policy research, according to a resolution approved by the AOA House of Delegates.
The changes concern the reclassification of cannabis to make it a schedule 2 drug, allowing it to be prescribed by medical professionals and possessed lawfully by anybody with a valid medical prescription.
Under current recommendations, people who use cannabis for conditions including chronic pain, arthritis, the side effects of chemotherapy and even the self-medication of brain and other tumours, will continue to be criminalised.
The cannabis industry has largely escaped negligence cases to date, mainly due to legal uncertainties - experts claim this ‘tort cease-fire’ is coming to an end.
In Colorado and Washington arrest rates for cannabis has fallen and crime clearance rates for violent crime, burglary, motor vehicle theft and property crime have shifted upward.
Preventive steps and remediative action are required to reduce the prevalence of contamination from microbes, heavy metals and, pesticides.
The market for cannabis and hemp products has seen a low-key but potentially huge step forward in recent weeks.